[go: up one dir, main page]

MX2009011068A - Agentes anti-angiogenicos y metodos de utilizacion. - Google Patents

Agentes anti-angiogenicos y metodos de utilizacion.

Info

Publication number
MX2009011068A
MX2009011068A MX2009011068A MX2009011068A MX2009011068A MX 2009011068 A MX2009011068 A MX 2009011068A MX 2009011068 A MX2009011068 A MX 2009011068A MX 2009011068 A MX2009011068 A MX 2009011068A MX 2009011068 A MX2009011068 A MX 2009011068A
Authority
MX
Mexico
Prior art keywords
angiogenesis
present disclosure
methods
angiogenic agents
preventing
Prior art date
Application number
MX2009011068A
Other languages
English (en)
Inventor
Zhican Qu
Anshu Mittal Roy
Subramaniam Ananthan
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of MX2009011068A publication Critical patent/MX2009011068A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento actual está generalmente relacionado al tratamiento o prevención de enfermedades asociadas con angiogénesis a través de administrar a un paciente compuestos que se han encontrado inhiben o sustancialmente reducen la angiogénesis. Compuestos empleados según el invento actual exhiben buena actividad anti-angiogénico así como demuestra un efecto profiláctico para la prevención y reducción sustancial de angiogénesis. Ejemplos de dichos compuestos incluyen Ritanserina, Amiodarona, Terfenadina, Perfenazina, Bitionol y Clomipramina.
MX2009011068A 2007-04-13 2008-04-14 Agentes anti-angiogenicos y metodos de utilizacion. MX2009011068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91164507P 2007-04-13 2007-04-13
PCT/US2008/060186 WO2009023299A2 (en) 2007-04-13 2008-04-14 Anti-angiogenic agents and methods of use

Publications (1)

Publication Number Publication Date
MX2009011068A true MX2009011068A (es) 2010-01-13

Family

ID=40351375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011068A MX2009011068A (es) 2007-04-13 2008-04-14 Agentes anti-angiogenicos y metodos de utilizacion.

Country Status (13)

Country Link
US (4) US8367737B2 (es)
EP (6) EP2420236B1 (es)
JP (4) JP5291700B2 (es)
KR (1) KR101519028B1 (es)
CN (3) CN101940571A (es)
AU (2) AU2008287285B2 (es)
BR (2) BRPI0810897A2 (es)
CA (4) CA2874595A1 (es)
EA (2) EA019919B1 (es)
ES (3) ES2534588T3 (es)
MX (1) MX2009011068A (es)
NZ (4) NZ592289A (es)
WO (1) WO2009023299A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101642451B (zh) * 2008-08-08 2013-04-24 湘北威尔曼制药股份有限公司 胺碘酮及其衍生物的新用途
WO2011041731A2 (en) * 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
US8865901B2 (en) 2009-10-02 2014-10-21 Fred Hutchinson Cancer Research Center Gain-of-function Bcl-2 inhibitors
EP2593093A1 (en) * 2010-07-16 2013-05-22 Merz Pharma GmbH & Co. KGaA Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US20140005260A1 (en) * 2012-06-28 2014-01-02 Tri-Service General Hospital Method for inhibiting cancer metastasis by amiodarone
CN103848985B (zh) * 2012-11-30 2018-03-02 杨子剑 含有舒尼替尼类似物结构的新化合物以及制备方法和用途
US10124008B2 (en) 2014-06-23 2018-11-13 Wisconsin Alumni Research Foundation Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations
US10369119B2 (en) * 2015-10-21 2019-08-06 Keck Graduate Institute Of Applied Life Sciences Inhibition of multiple pathogenic agents using bithionol
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN115708821B (zh) * 2022-11-30 2024-07-26 中国海洋大学 一种海洋真菌来源化合物在制备抗肿瘤血管生成的药物中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
US3248401A (en) 1966-04-26 Diethylaminoe hoxybenzoyl benzofurans
US2849494A (en) 1956-05-17 1958-08-26 Monsanto Chemicals 2, 2'-thiobis
US2860138A (en) 1956-11-21 1958-11-11 Schering Corp Carbamate esters of hydroxyalkyl piperazino alkyl phenothiazines
NL110232C (es) 1958-12-06
US3506720A (en) 1963-02-22 1970-04-14 Geigy Chem Corp Halogenated hydroxy-diphenyl ethers
US3878217A (en) 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4485107A (en) 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4533665A (en) 1983-07-27 1985-08-06 Janssen Pharmaceutica [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
ATE135216T1 (de) * 1989-08-21 1996-03-15 Beth Israel Hospital Verwendung von spiperone-derivate zur immunosuppression
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
FI930552L (fi) 1990-08-10 1993-02-22 Inst Of Organic Chemistry Czec Nytt foerfarande foer framstaellning av nukleotider
EP0547172A1 (en) * 1990-09-04 1993-06-23 Miles Inc. REGULATION OF T-CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR
ATE139447T1 (de) * 1990-12-18 1996-07-15 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
RO116043B1 (ro) * 1992-08-03 2000-10-30 Sepracor Inc Compozitie farmaceutica
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
JP4063868B2 (ja) * 1995-02-28 2008-03-19 ザ ジレット カンパニー 毛髪成長を抑制するための脈管形成抑制剤の使用
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
TW369536B (en) 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
JP4369994B2 (ja) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのａｔ▲下１▼レセプターアンタゴニスト
US5801564A (en) 1996-06-28 1998-09-01 Symbios, Inc. Reduced skew differential receiver
CA2261619C (en) 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
WO1998015548A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S 1,4-disubstituted piperazines
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU775289B2 (en) * 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
WO2000032193A1 (en) * 1998-12-02 2000-06-08 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
US6472393B1 (en) 1999-01-13 2002-10-29 Genentech, Inc. Serine protease inhibitors
WO2000045165A1 (en) * 1999-02-01 2000-08-03 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
KR20020093824A (ko) 2000-02-29 2002-12-16 미쯔비시 웰 파마 가부시키가이샤 포스포네이트 뉴클레오티드 화합물
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
WO2002060375A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Diphenyl ether derivatives and their uses as heparanase inhibitors
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
JP4393863B2 (ja) * 2001-06-18 2010-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 視神経細胞保護剤
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
DE10206941A1 (de) * 2002-02-19 2003-09-25 Goetz Nowak Neue Arzneimittel
WO2003106660A2 (en) * 2002-06-17 2003-12-24 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
IL166156A0 (en) * 2002-07-09 2006-01-15 Point Therapeutics Inc Boroproline compound combination therapy
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
FR2849382A1 (fr) 2002-12-26 2004-07-02 Urogene Utilisation du gene htr2b pour le traitement du cancer de la prostate
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
WO2004080445A1 (en) * 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
WO2004105696A2 (en) * 2003-05-23 2004-12-09 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
CN1562930A (zh) * 2004-03-31 2005-01-12 深圳中药及天然药物研究中心 多卤取代二苯醚类衍生物的制备和医药用途
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
KR20060130406A (ko) * 2005-06-14 2006-12-19 이제호 Ｒａｓ 신호전달경로를 표적으로 하는 혈관신생, 세포증식및 세포전이 억제제
US20060287301A1 (en) * 2005-06-17 2006-12-21 Mcnair Douglas Novel formulations for phenothiazines, including fluphenazine and its derivatives
WO2007005670A2 (en) * 2005-06-30 2007-01-11 The Research Foundation Of The State University Of New York Natural and synthetic sulfoxide, selenone and selenoxide analogs and polymer conjugated forms thereof for the modulation of angiogenesis
CN101384614A (zh) * 2005-08-15 2009-03-11 加利福尼亚大学董事会 Vegf活化的fas配体
JP2007084508A (ja) * 2005-09-26 2007-04-05 Shiseido Co Ltd 新規血管内皮増殖因子発現阻害剤
JP2009510115A (ja) 2005-09-29 2009-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニン受容体に関連する疾患の治療に有用な５−ｈｔ２ａセロトニン受容体モジュレーターの薬学的組成物
US20070225238A1 (en) * 2006-02-24 2007-09-27 Charlier Henry A Jr Inhibitors of carbonyl reductase for treatment using anthracyclines
GB0701170D0 (en) 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof

Also Published As

Publication number Publication date
EP2420238A2 (en) 2012-02-22
NZ608343A (en) 2014-09-26
CN102772415A (zh) 2012-11-14
KR101519028B1 (ko) 2015-05-11
CN101940571A (zh) 2011-01-12
JP2013166802A (ja) 2013-08-29
CN101801386B (zh) 2013-09-04
EP2161023A3 (en) 2010-12-29
AU2008287285A1 (en) 2009-02-19
JP2015003914A (ja) 2015-01-08
JP2010523719A (ja) 2010-07-15
EP2161023A2 (en) 2010-03-10
EP2420239B1 (en) 2015-01-14
US20100204338A1 (en) 2010-08-12
US20100120745A1 (en) 2010-05-13
BRPI0810621A2 (pt) 2017-06-06
EP2420236A3 (en) 2012-06-27
AU2009238237B2 (en) 2013-02-07
US20150164873A1 (en) 2015-06-18
KR20090130100A (ko) 2009-12-17
WO2009023299A2 (en) 2009-02-19
CA2681267C (en) 2013-11-19
AU2009238237A1 (en) 2009-12-03
EP2420238A3 (en) 2012-03-07
EA019919B1 (ru) 2014-07-30
EA200970947A1 (ru) 2010-04-30
NZ580495A (en) 2011-05-27
ES2534589T3 (es) 2015-04-24
EP2139325B1 (en) 2015-01-14
WO2009023299A3 (en) 2009-05-22
EA200970948A1 (ru) 2010-08-30
ES2534588T3 (es) 2015-04-24
EP2420239A3 (en) 2012-07-11
NZ592289A (en) 2013-03-28
US8367737B2 (en) 2013-02-05
EP2420236A2 (en) 2012-02-22
JP2010159265A (ja) 2010-07-22
CA2874595A1 (en) 2009-02-19
CA2826272A1 (en) 2009-02-19
CA2681267A1 (en) 2009-02-19
JP5291700B2 (ja) 2013-09-18
EP2420230A3 (en) 2012-06-27
BRPI0810897A2 (pt) 2016-07-26
EP2139325A2 (en) 2010-01-06
EP2420239A2 (en) 2012-02-22
NZ581134A (en) 2011-04-29
EP2420236B1 (en) 2015-01-14
WO2009023299A9 (en) 2009-04-02
EP2420230A2 (en) 2012-02-22
AU2008287285B2 (en) 2013-05-16
ES2534345T3 (es) 2015-04-21
CA2683316A1 (en) 2009-02-19
CN101801386A (zh) 2010-08-11
EP2139325A4 (en) 2011-09-14
US20130123240A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
MX2009011068A (es) Agentes anti-angiogenicos y metodos de utilizacion.
MX2014001180A (es) Moduladores del transporte nuclear y usos de los mismos.
IN2012DN00624A (es)
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EP4234545A3 (en) Hydrazide containing nuclear transport modulators and uses thereof
WO2012065958A9 (en) Method of treating contrast-induced nephropathy
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
IN2012DN02081A (es)
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
MX356025B (es) Uso de glicopirrolato para tratar taquicardia.
TN2013000283A1 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
ZA201008160B (en) Compositions for the treatment of hair loss
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
MX2010001303A (es) Compuestos terapeuticos.
DE602008002598D1 (en) Cyclohexylderivate
MX2012004087A (es) Sulfonamidas para la prevencion de diabetes.
MX2010010000A (es) Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
TN2015000142A1 (en) Use of pidotimod to treat psoriasis
EP3925608A3 (en) Use of phenoxypropylamine compounds to treat or improve at least one disorder or parameter of sleep
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Legal Events

Date Code Title Description
FG Grant or registration